Method for treating calcium imbalance and improving calcium absorption in mammals

• US 4,225,596 A
• Filed: 10/13/1978
• Issued: 09/30/1980
• Est. Priority Date: 10/13/1978
• Status: Expired due to Term

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: DeLuca, Hector F.
• Primary Examiner(s): Robinson, Douglas W.
• Application Number:
  US05/951,320
• Time in Patent Office: 718 Days
• Field of Search: 424/236
• US Class Current: 514/167
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems

Abstract

A method for treating or preventing metabolic bone disease characterized by loss of bone mass and of improving the calcium balance and calcium absorption of mammals, particularly of women in the post menopausal state, by administering at least one compound having the formulae ##STR1## where R₁, R₂ and R₄ are each selected from the group consisting of hydrogen, hydroxyl, lower alkyl, acyl and O-alkyl and R₃ is selected from the group consisting of hydrogen, hydroxyl, keto, lower alkyl, acyl and O-alkyl.

Claims

1. A method for increasing the calcium absorption and retention within the body of mammals displaying evidence of, or having a physiological tendency toward, loss of bone mass, which comprises administering internally to said mammals, in a therapeutically effective amount, at least one compound selected from the group consisting of 1α

-hydroxycholecalciferol, 1α

-hydroxyergocalciferol, 1,25-dihydroxycholecalciferol, 1,25-dihydroxyergocalciferol and 1,24,25-trihydroxycholecalciferol.

2. The method of claim 1 where the compound is administered in an amount from about one-tenth microgram to about one microgram per day.

3. The method of claim 1 wherein the compound, in solution in a liquid vehicle ingestible by and nontoxic to said mammals is administered orally in encapsulated form.

4. The method of claim 1 wherein the compound is administered to women during and subsequent to menopause.

5. The method of claim 1 wherein the compound is administered to women prior to the onset of menopause.